Clinical Research Directory

Inclusion Criteria: * Patient (males and females) aged between 18 and 84 years (limits included); * Patient able to understand the nature and purpose of the study, including possible risks and side effects; * Patient able to provide written Informed Consent, in accordance with good clinical practice and current legislation; * Pain ≥ 40 mm on the VAS score in the target knee for at least 2 months; * Patient with knee osteoarthritis assessed radiographically, grade 1 to 3 according to the Kellgren-Lawrence scale (K-L); * Body Mass Index (BMI) ≤ 35; * Patient who will benefit from this treatment; * Patient available for the entire study period; * Patient able to cooperate and meet the requirements of the clinical investigation plan. Exclusion Criteria: * Patient with knee osteoarthritis, assessed radiographically, grade 4 by the K-L scale; * Patient presenting ongoing inflammation/infection at the level of the joint being investigated; * Patient with abundant intra-articular effusion; * Patient with symptoms of viral or bacterial infections or similar; * Patient with insertion point of the joint infected or in the presence of a skin disease; * Simultaneous treatment with disinfectants containing quaternary ammonium salts or chlorhexidine; * Patient with known or potential allergy or hypersensitivity and/or history of allergic reactions to one of the components of the medical device; * Concomitant treatments with thrombolytic or anticoagulant therapies, for less than 2 weeks prior to the screening visit; * Intra-articular treatments carried out in the last 3 months (9 months if with products containing hyaluronic acid) of the target joint; * Topical treatments of the target joint in progress or performed within 1 week of the screening visit; * Taking NSAIDs and/or paracetamol as rescue treatment for more than two consecutive days; * Surgical interventions of prosthetic replacement in the target joint; * Physiotherapy and instrumental physical therapy treatments for the target joint performed in the last 2 weeks prior to the screening visit, and during the study period; * Participation in another clinical trial within 60 days prior to the screening visit; * Evidence of severe or uncontrolled systemic disease or any other significant disorder (e.g. haemophilia, bleeding disorders etc.); which do not allow participation in the study or could compromise the results. * Patients who are pregnant or breastfeeding; * Subject unable to follow clinical investigation procedures and follow-up visits; * Any other medical condition which could influence participation in the clinical investigation or compromise its results.